On 31 March 2026, France will shut the door on its five-year medical cannabis pilot.
On 1 April, the country enters a permanent, pharmaceutical-style regime — one that will determine access, pricing, supply, and prescriber rights for the next decade.
For an industry long locked out of France, this moment is arguably more consequential than Germany’s 2024 reforms. It marks the opening of a market that has, until now, been hermetically sealed: 3,209 patients enrolled over three years, free medicine, and a narrow circle of hospital specialists allowed to prescribe.
But one thing must be understood clearly:
Generalisation is not Liberalisation.
France is not becoming Germany. It is becoming France — and the new framework is strict, clinical, and technically demanding.
With the final regulatory decisions being drafted now, here is the real state of play.
France Medical Cannabis Prescribers: The Training Bottleneck
The pilot’s biggest flaw was its prescriber bottleneck. Only hospital-based specialists in areas like pain and palliative care could authorise treatment. This kept the patient population artificially capped; of the 3,209 patients enrolled since 2021, only 1,849 remain under active treatment.
The permanent regime is designed to widen this channel. Draft texts notified to the European Commission indicate:
- an expanded prescriber base
- the possibility for General Practitioners (GPs) to renew treatment cycles
- a shift toward ongoing community care
But there is a catch — and it’s enormous:
Mandatory training certification remains the real gatekeeper.
According to the Augur Associates’ State of the Medical Cannabis Industry in France 2025 report, France currently has 2,291 trained healthcare professionals:
- 531 specialist doctors
- 213 general practitioners
- 1,471 pharmacists (472 hospital, 999 retail)
While this represents significant infrastructure investment, the report notes a critical structural imbalance: “531 specialist doctors compared with 213 GPs working in outpatient clinics highlights the importance of strengthening the integration of outpatient medicine into the system.”
If the market scales to government projections of 5,454 patients in 2026 — or Prohibition Partners’ estimate of 450,000+ patients by 2035 — each prescriber would need to manage 2–200+ patients. Unless the Haute Autorité de Santé (HAS) accelerates or simplifies the training pathway before April, “generalisation” will arrive with insufficient prescribers to meet demand.
📊 PRESCRIBER CAPACITY GAP
France 2026: 2,291 trained professionals → 5,454 projected patients (2.4 patients each)
France 2035: 2,291 trained professionals → 457,129 projected patients (200 patients each)
That’s a 247x patient increase without a clear prescriber scaling plan.
Source: Augur Associates 2025
“Transitions from pilots to permanent regimes carry the highest risk for patient access continuity,” notes Benjamin-Alexandr Jeanroy of Augur Associates. “Without a scalable prescriber pathway built early, care gaps become inevitable as demand surges.”
Medical Cannabis Products France: Flower in a Pharmaceutical Straitjacket
If stakeholders are expecting a German-style flower market, they will be disappointed.
France remains culturally — and politically — allergic to combustion. Early drafts raised fears that flower would be prohibited entirely. Instead, the compromise is uniquely French:
Flower will be permitted, but only in sealed capsules for vaporisation using approved medical devices.
The Augur report describes this as a “restrictive measure taken to ease the Interior ministry.” During the pilot programme, the Mighty Medic® vaporisation device (manufactured by Storz & Bickel, owned by Canopy Growth) was the approved standard. Pharmacists provided mandatory patient training using demonstration kits, ensuring controlled, pharmaceutical-grade delivery.
This single technical requirement transforms the entire supply landscape:
- Producers must align their flower with specific monographs for vaporisation
- Products must pair with devices meeting medical device regulations
- Traditional exporters cannot simply ship GMP flower into the market
- Dried flower in loose form is explicitly excluded
This leans heavily in favour of integrated pharmaceutical manufacturers and sophisticated multinationals, not craft growers or opportunistic entrants.
France Cannabis Supply Chain: The “Made in France” Gap (2026–2028)
French policymakers have been clear: they want a sovereign French supply chain (la filière) for French patients.
But ambition does not equal capacity.
Domestic cultivators are only now progressing through GMP certification, and none are positioned to serve national demand by April 2026. A realistic timeline puts full domestic coverage closer to 2028.
This creates a two- to three-year import reliance window, in which international suppliers — particularly those in Canada, Denmark, and Portugal — will be essential.
The strategic race is already underway:
- Who will secure pharmacy distribution partnerships?
- Who can meet France’s device-linked flower requirements?
- Who can supply consistent GMP volumes at French price points?
Learning from Germany’s Early-Mover Advantage
Germany’s 2024 transition provides a clear case study in the power of early positioning.
Tilray, which acquired pharmaceutical distributor CC Pharma in 2019, built distribution relationships with over 13,000 German pharmacies before the regulatory framework changed. When Germany’s Federal Institute for Drugs and Medical Devices (BfArM) issued its first cultivation license under the new MedCanG framework in July 2024, Tilray was first in line. The company now holds approximately 20% of Germany’s medical cannabis market.
Aurora Cannabis followed a similar strategy, securing one of only three in-country cultivation licenses. Together with Tilray, Four20 Pharma, Canopy Growth, and CannaMedical, these five early entrants captured over 70% of Germany’s medical flower market within 18 months of the regulatory transition.
The lesson for France is unambiguous: companies establishing distribution footprints and device partnerships now will dominate the early market. Those waiting for the framework to “settle” will find the pharmacy networks and device manufacturers already locked into exclusive relationships.
Medical Cannabis Reimbursement France: The €100m Question
In France, reimbursement is not an accessory — it is the foundation of market viability.
The pilot succeeded because medicine was fully covered by the state. The permanent regime will succeed or fail based on two decisions still pending:
1. The Service Médical Rendu (SMR) rating
If HAS deems cannabis to have “insufficient medical value,” it risks exclusion from reimbursement altogether.
2. The CEPS price-setting decision
Even with a positive SMR, the Comité Économique des Produits de Santé (CEPS) may impose tight price ceilings that limit margins for producers and distributors.
The difference is dramatic:
- No reimbursement → niche, luxury-level market; ~5,000–10,000 patients
- 30% reimbursement → moderate accessibility; ~50,000+ patients
- 65% reimbursement → mainstream medical adoption; 100,000+ patients within 24 months
According to Prohibition Partners’ projections cited in the Augur report, the French market could grow from €9.6 million in 2026 to €806 million by 2035 — but only if reimbursement structures support patient access.
No other single factor will influence the market more.
France Medical Cannabis April 2026: What Cannabis Europa Paris Will Decide
The next eight weeks will determine:
- who can prescribe
- which products qualify
- which devices pass
- which suppliers enter
- whether the state will pay
- and what the French medical cannabis market will look like until at least 2030
These rules are being finalised right now.
The Framework Locks on April 1.
The Final Briefing Is February 19.
Cannabis Europa Paris brings together the companies, analysts, and advisors shaping France’s entry into permanent medical cannabis—weeks before the market opens.